Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
FLNA
FILANA THERAPEUTICS, INC.
NASDAQ
$0.73
▲ UP 0.83% (0.01)

KEY STATISTICS

Market Cap$35.07 M
52w High$4.98
52w Low$0.67
Dividend Yield—
Frequency—
P/E-0.83
Volume122.73K
Shares Out.48.31M

COMPANY

LEADERSHIP

Richard Jon Barry
CHIEF EXECUTIVE
Richard Jon Barry

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 14, 2000
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
19

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.—
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2017-05-10Reverse1:7

PRICE

$0.73 ▲ UP 0.83% (+$0.01)
OVERLAYS
$0.71$0.72$0.73$0.739:33 AM10:37 AM11:41 AM12:46 PM1:50 PM2:54 PM3:58 PM0.73

About Filana Therapeutics, Inc.

https://www.filanatx.com ↗

Filana Therapeutics, Inc., founded in 1998 and based in Austin, TX, develops novel drugs and diagnostics, including PTI-125 and PTI-125Dx, aimed at treating Alzheimer’s disease.

INDUSTRY

Biotechnology

A PRODUCT FILANA THERAPEUTICS, INC. IS KNOWN FOR

Simufilam
Simufilam

Simufilam, an investigational oral small molecule from Filana Therapeutics, shifted focus from Alzheimer's to potential treatment of TSC-related epilepsy and CNS disorders linked to filamin A after Phase 3 trial setbacks.

COMPETITORS

COMPETITOR
ABBV COMPARE
AVXL COMPARE
BIIB COMPARE
CGTX COMPARE
LLY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book4
Overall Score2